Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)

PHASE3CompletedINTERVENTIONAL
Enrollment

388

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

February 29, 2016

Conditions
Vaso-occlusive CrisisSickle Cell Disease
Interventions
DRUG

Saline

DRUG

MST-188

Trial Locations (72)

10101

Research Center, Santo Domingo

10457

Bronx Lebanon Hospital, The Bronx

10514

Research Center, Santo Domingo

11040

Cohen Children's Medical Center, New Hyde Park

11215

NY Methodist, Brooklyn

14642

Golisano Children's Hospital at URMC, Rochester

15224

Children's Hospital of Pittsburgh, Pittsburgh

15232

University of Pittsburgh Medical Center, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

19803

Al DuPont Hospital for Children, Wilmington

20060

Howard University, Washington D.C.

21205

Johns Hopkins, Baltimore

21215

The Herman and Walter Samuelson Children's Hospital at Sinai, Baltimore

22908

University of Virginia Medical Center, Charlottsville

23298

Children's Hospital of Richmond, Richmond

23507

Children's Hospital of the King's Daughters, Norfolk

27599

University of North Carolina-Chapel Hill, Chapel Hill

27710

Duke University Medical Center, Durham

27834

East Carolina University, Greenville

29425

The Medical University of South Carolina, Charleston

30303

Grady Memorial Hospital, Atlanta

30912

Georgia Regents University, Augusta

33021

Joe Dimaggio Children's Hospital, Hollywood

33136

University of Miami, Miami

33155

Miami Children's Hospital, Miami

33606

Tampa General Hospital, Tampa

33701

All Children's Hospital, St. Petersburg

33908

Children's Hospital of SouthWest Florida, Fort Myers

36688

University of South Alabama, Mobile

37403

T.C. Thompson Children's Hospital, Chattanooga

39216

University of Mississippi Medical Center, Jackson

40202

University of Louisville/Kosair Children's Hospital, Louisville

44106

Rainbow Babies and Children's Hospital, Cleveland

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

46804

Fort Wayne Lutheran Hospital, Fort Wayne

48201

Children's Hospital of Michigan-Wayne State University, Detroit

48503

Hurley Research Center, Flint

52242

University of Iowa-Children's Hospital, Iowa City

60611

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

60612

Children's Hospital at the University of Illinois, Chicago

70118

Children's Hospital of New Orleans, New Orleans

70808

Our Lady of the Lake Children's Hospital, Baton Rouge

76104

Cook's Children Hospital, Fort Worth

77030

Texas Children's Hospital, Houston

85016

Phoenix Children's Hospital, Phoenix

90502

Harbor-UCLA Medical Center, Torrence

92123

Rady Children's Hosptial, San Diego

94609

UCSF Benioff Children's Hospital, Oakland

95817

University of California Davis Health System, Sacramento

97227

Randall Children's Hospital, Portland

08903

Rutger's University, New Brunswick

Unknown

Reearch Center, Antwerp

Research Center, Brussels

Research Center, Edgem

Research Center, Liège

Research Center, Montegnée

Resaerch Center, Rio de Janerio

Research Center, São Paulo

Research Center, Kingston

Research Center, Irbid

Research Center, Beirut

Research Center, Tripoli

Research Center - Child Health Department, Muscat

Research Center, Muscat

Research Center Hospital del Nino, Panama City

Research Center Hospital of Pediatric Specialities, Panama City

Research Center Metropolitan Hospital, Panama City

Research Center, Madrid

Research Center, Adana

Research Center, Istanbul

Research Center, Mersin

Sponsors
All Listed Sponsors
lead

Mast Therapeutics, Inc.

INDUSTRY

NCT01737814 - Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) | Biotech Hunter | Biotech Hunter